Randomized trial: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Triplet therapy slows refractory multiple myeloma – MedicalXpress